Compare Hut 8 Corp (HUT) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Sana Biotechnology Inc — how do they compare? Hut 8 Corp trades at $90.81 (market cap $10.94B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Hut 8 Corp is far larger — about 9.7× Sana Biotechnology Inc's market cap, and Hut 8 Corp is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| HUT | SANA | |
|---|---|---|
Market Cap | $10.94B | $1.13B |
Sector | Technology | Health |
52-Week High | $133.02 | $5.92 |
52-Week Low | $21.37 | $2.68 |
Enterprise Value | $18.38B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HUT trades at $90.77, up 5.97% on the day, amid a broader neocloud stock rally. The technical picture is bearish with resistance at $92 and support at $87. Fundamentally, the company reported a net loss of $226.15 million in 2025 despite revenue growth, with a negative net income margin of -188.59%. Recent news highlights a significant $26.6 billion contracted backlog and $7.5 billion in project financing for AI data center development, driving investor optimism about its strategic pivot.
The outlook is mixed: strong analyst buy ratings (93.75%) and a $165.11 price target suggest upside, but persistent losses, high valuation ratios, and execution risks on new projects pose challenges. The stock's near-term direction will hinge on translating its AI infrastructure backlog into profitable growth and achieving positive cash flow.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
